Medtech company Omnia Medical has commercially launched its PsiF DNA Sacroiliac Joint Stabilization System.
The system is intended to be used for sacroiliac joint fusion to treat conditions including degenerative sacroiliitis and sacroiliac joint disruptions, according to a Jan. 20 news release from Omnia Medical.
Its double-helix architecture leverages autograft bone from both the ilium and the sacrum to support arthrodesis and long-term joint stabilization.
The FDA provided 510(k) clearance for the system in May 2025, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
